Aerie Pharmaceuticals IncのQuick ratio
Aerie Pharmaceuticals IncのQuick ratioは何ですか。
Aerie Pharmaceuticals IncのQuick ratioは1.92です。
Quick ratioの定義は何ですか。
当座比率は、短期債務を即座に満たすために迅速な資産を使用する企業の能力を測定する流動性比率です。
The quick ratio is the ratio between quick or liquid assets and current liabilities. Quick assets include those current assets that presumably can be quickly converted to cash at close to their book values. A normal liquid ratio is considered to be 1. A company with a quick ratio of less than 1 cannot at the time fully pay its current liabilities or short-term obligations. This ratio is considered to be a much reliable tool for assessment of liquidity position of companies.
NASDAQのセクタHealth CareにおけるQuick ratioの企業と比べるAerie Pharmaceuticals Inc
Aerie Pharmaceuticals Incは何をしますか。
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.
Aerie Pharmaceuticals Incと類似のquick ratio
- Invinity SystemsのQuick ratioは1.92です。
- DXP EnterprisesのQuick ratioは1.92です。
- Vimta LabsのQuick ratioは1.92です。
- China Oriented InternationalのQuick ratioは1.92です。
- Provention BioのQuick ratioは1.92です。
- PRGX Global IncのQuick ratioは1.92です。
- Aerie Pharmaceuticals IncのQuick ratioは1.92です。
- Shangri-La AsiaのQuick ratioは1.92です。
- AphriaのQuick ratioは1.92です。
- Aphria IncのQuick ratioは1.92です。
- Vertical InternationalのQuick ratioは1.92です。
- Timken IndiaのQuick ratioは1.92です。
- Big Ridge GoldのQuick ratioは1.92です。